Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 8 | 2023 | 207 | 1.620 |
Why?
|
| beta-Lactamases | 4 | 2023 | 42 | 1.620 |
Why?
|
| Enterobacteriaceae | 3 | 2019 | 16 | 1.390 |
Why?
|
| Enterobacteriaceae Infections | 3 | 2019 | 20 | 1.380 |
Why?
|
| Child | 10 | 2023 | 614 | 1.050 |
Why?
|
| Child, Preschool | 8 | 2023 | 320 | 0.920 |
Why?
|
| Infant, Newborn | 9 | 2021 | 312 | 0.860 |
Why?
|
| Case-Control Studies | 6 | 2023 | 256 | 0.830 |
Why?
|
| Escherichia coli | 1 | 2023 | 18 | 0.800 |
Why?
|
| Adolescent | 8 | 2022 | 989 | 0.800 |
Why?
|
| Fluoroquinolones | 2 | 2023 | 10 | 0.790 |
Why?
|
| Plasmids | 2 | 2023 | 28 | 0.790 |
Why?
|
| Humans | 23 | 2023 | 12240 | 0.730 |
Why?
|
| Staphylococcal Infections | 3 | 2015 | 81 | 0.730 |
Why?
|
| Cross Infection | 1 | 2023 | 129 | 0.730 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2021 | 2 | 0.680 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2021 | 3 | 0.680 |
Why?
|
| Myocarditis | 1 | 2021 | 4 | 0.670 |
Why?
|
| Gammaproteobacteria | 1 | 2021 | 3 | 0.660 |
Why?
|
| Infant | 7 | 2021 | 277 | 0.660 |
Why?
|
| Bacterial Infections | 1 | 2021 | 26 | 0.650 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 7 | 0.590 |
Why?
|
| Klebsiella Infections | 1 | 2019 | 35 | 0.580 |
Why?
|
| Klebsiella pneumoniae | 1 | 2019 | 38 | 0.570 |
Why?
|
| Genotype | 1 | 2019 | 169 | 0.560 |
Why?
|
| Molecular Typing | 2 | 2019 | 6 | 0.550 |
Why?
|
| Ceftriaxone | 1 | 2017 | 2 | 0.510 |
Why?
|
| Chicago | 4 | 2021 | 453 | 0.500 |
Why?
|
| Raltegravir Potassium | 1 | 2016 | 2 | 0.500 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2023 | 39 | 0.490 |
Why?
|
| Drug Hypersensitivity Syndrome | 1 | 2016 | 3 | 0.490 |
Why?
|
| Eosinophilia | 1 | 2016 | 13 | 0.490 |
Why?
|
| Risk Factors | 5 | 2021 | 1049 | 0.470 |
Why?
|
| Gingivitis, Necrotizing Ulcerative | 1 | 2015 | 1 | 0.460 |
Why?
|
| Osteosarcoma | 1 | 2015 | 21 | 0.450 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 59 | 0.440 |
Why?
|
| Male | 9 | 2021 | 6815 | 0.420 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2020 | 40 | 0.410 |
Why?
|
| Enterovirus Infections | 1 | 2013 | 2 | 0.400 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2013 | 3 | 0.400 |
Why?
|
| Meningoencephalitis | 1 | 2013 | 4 | 0.400 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 5 | 0.400 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2013 | 15 | 0.400 |
Why?
|
| Staphylococcus aureus | 1 | 2013 | 36 | 0.390 |
Why?
|
| beta-Lactam Resistance | 1 | 2012 | 1 | 0.370 |
Why?
|
| Carbapenems | 1 | 2012 | 11 | 0.370 |
Why?
|
| Pandemics | 3 | 2021 | 126 | 0.340 |
Why?
|
| Young Adult | 3 | 2019 | 863 | 0.330 |
Why?
|
| Female | 7 | 2021 | 6974 | 0.310 |
Why?
|
| Tertiary Care Centers | 2 | 2019 | 26 | 0.290 |
Why?
|
| Adult | 4 | 2022 | 3557 | 0.290 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 151 | 0.270 |
Why?
|
| Staphylococcaceae | 1 | 2008 | 1 | 0.270 |
Why?
|
| Endocarditis, Bacterial | 1 | 2008 | 6 | 0.270 |
Why?
|
| Molecular Epidemiology | 2 | 2021 | 16 | 0.270 |
Why?
|
| United States | 4 | 2022 | 989 | 0.230 |
Why?
|
| Multilocus Sequence Typing | 1 | 2023 | 8 | 0.200 |
Why?
|
| Bacterial Proteins | 2 | 2021 | 48 | 0.200 |
Why?
|
| Phylogeny | 1 | 2023 | 35 | 0.200 |
Why?
|
| Overweight | 1 | 2022 | 35 | 0.170 |
Why?
|
| Minority Groups | 1 | 2022 | 40 | 0.170 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 153 | 0.170 |
Why?
|
| Neutropenia | 1 | 2021 | 8 | 0.170 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 8 | 0.170 |
Why?
|
| Hypotension | 1 | 2021 | 11 | 0.170 |
Why?
|
| Tachycardia | 1 | 2021 | 6 | 0.170 |
Why?
|
| Prevalence | 2 | 2019 | 175 | 0.170 |
Why?
|
| Fever | 1 | 2021 | 18 | 0.170 |
Why?
|
| Bradycardia | 1 | 2021 | 15 | 0.170 |
Why?
|
| Mandatory Programs | 1 | 2021 | 2 | 0.170 |
Why?
|
| Federal Government | 1 | 2021 | 3 | 0.170 |
Why?
|
| State Government | 1 | 2021 | 3 | 0.170 |
Why?
|
| Local Government | 1 | 2021 | 3 | 0.170 |
Why?
|
| Shock, Septic | 1 | 2021 | 16 | 0.170 |
Why?
|
| Masks | 1 | 2021 | 4 | 0.170 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 38 | 0.170 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2021 | 26 | 0.160 |
Why?
|
| Universal Precautions | 1 | 2020 | 6 | 0.160 |
Why?
|
| Siderophores | 1 | 2020 | 1 | 0.160 |
Why?
|
| Lactams | 1 | 2020 | 2 | 0.160 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 400 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 8 | 0.160 |
Why?
|
| Obesity | 1 | 2022 | 156 | 0.160 |
Why?
|
| Infection Control | 2 | 2022 | 76 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 45 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 48 | 0.150 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 22 | 0.150 |
Why?
|
| Community-Acquired Infections | 1 | 2019 | 25 | 0.150 |
Why?
|
| Retrospective Studies | 2 | 2021 | 1467 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 46 | 0.130 |
Why?
|
| Bilirubin | 1 | 2017 | 3 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 13 | 0.130 |
Why?
|
| Drug Eruptions | 1 | 2016 | 6 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2015 | 30 | 0.110 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 25 | 0.110 |
Why?
|
| Critical Illness | 1 | 2015 | 53 | 0.110 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 55 | 0.110 |
Why?
|
| Enterovirus B, Human | 1 | 2013 | 2 | 0.100 |
Why?
|
| Ampicillin | 1 | 2013 | 4 | 0.100 |
Why?
|
| Pregnant Women | 1 | 2013 | 9 | 0.100 |
Why?
|
| Carrier State | 1 | 2013 | 29 | 0.100 |
Why?
|
| Gentamicins | 1 | 2013 | 17 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 726 | 0.100 |
Why?
|
| Urban Population | 1 | 2013 | 78 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 71 | 0.100 |
Why?
|
| Pregnancy | 1 | 2013 | 193 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2013 | 214 | 0.090 |
Why?
|
| Time Factors | 1 | 2013 | 695 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2013 | 817 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2013 | 827 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2015 | 1478 | 0.080 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2017 | 8 | 0.060 |
Why?
|
| Animals | 2 | 2020 | 2092 | 0.060 |
Why?
|
| Health Facilities | 1 | 2022 | 12 | 0.050 |
Why?
|
| Leadership | 1 | 2021 | 55 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 56 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 4 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2020 | 27 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 14 | 0.040 |
Why?
|
| Blood-Borne Pathogens | 1 | 2020 | 3 | 0.040 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2020 | 1 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 2 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2020 | 6 | 0.040 |
Why?
|
| Half-Life | 1 | 2020 | 7 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2020 | 12 | 0.040 |
Why?
|
| Gram-Negative Bacteria | 1 | 2020 | 12 | 0.040 |
Why?
|
| Binding Sites | 1 | 2020 | 39 | 0.040 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2020 | 17 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 21 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 38 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 79 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 338 | 0.040 |
Why?
|
| Mice | 1 | 2020 | 760 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 115 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 68 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 196 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 46 | 0.030 |
Why?
|
| Illinois | 1 | 2015 | 110 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 101 | 0.030 |
Why?
|